Early changes in flow cytometric DNA profiles induced by californium-252 neutron brachytherapy in squamocellular carcinomas of the uterine cervix.
Ninety-five squamocellular carcinomas of the uterine cervix, clinical Stages II and III, were treated by either four schedules combining 252-californium neutron-gamma-radiotherapy with different proportions of a neutron component (9, 6 and 3 Gy) or gamma-irradiation alone. Flow cytometric DNA profiles were obtainable in 72 cases before treatment and 56 cases were monitored for DNA content by flow cytometry (FCM) in weekly intervals by analysis of sequential microbiopsies for one month during and after radiotherapy. DNA aneuploidy was reduced from 40% (25/63) to 19% (9/47) one week within therapy in neutron-treated groups, but not after initial gamma-radiotherapy alone. Extinction of DNA aneuploid subpopulations occurred after neutron therapy in all remaining aneuploid tumors (9/9) during further monitoring, but only in 40% (2/5) of tumors after sole gamma-irradiation. In contrast, proliferation index by more than 50% was more often achieved in groups with a higher gamma-radiation component than after neutrons only. When all therapy-induced DNA flow cytometric events are taken together for evaluation of the effects of various radiotherapy schedules, it appears that the regimen with the maximal neutron dose may not be optimal for all tumors. It is hypothesized that the differences in the early flow cytometric DNA profiles may select the DNA aneuploid squamous cell uterine cervical carcinomas as candidates for combined neutron-brachytherapy, while highly proliferating DNA near-diploid tumors may profit more from treatment with a higher gamma-radiotherapy component. However, these early DNA flow cytometric findings need to be correlated with clinical course of the disease to validate this hypothesis, a process which will be completed at the end of the expected five-year clinical outcome in 2000.
Masaryk Memorial Cancer Institute, Brno, Czech Republic.
T
T
Tacev
J
J
Zaloudík
L
L
Janáková
V
V
Vagunda
D000782:Aneuploidy; D001706:Biopsy; D001918:Brachytherapy; D002142:Californium / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000532:radiotherapy*; D002455:Cell Division / Q000528:radiation effects; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics* / Q000528:radiation effects*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D009502:Neutrons / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000532:radiotherapy*
D004273:DNA, Neoplasm; D002142:Californium